Drugs / Spebrutinib
Spebrutinib
also known as
CC-292 · AVL-292 · AVL-292 BESYLATE · BTK INHIBITOR CC-292 · CC-292 BESYLATE · ESPEBRUTINIB · LMK-435 · SPEBRUTINIB (CC-292) · +2 more
Small molecule targets BTK via inhibition
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02433457 | May → Sep 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02031419 | Dec 2013 → Dec 2023 | diffuse large B-cell lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT01766583 | Feb 2013 → Nov 2014 | lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 1 | NCT01732861 | Dec 2012 → Jan 2019 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01744626 | Dec 2012 → Dec 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01692184 | Aug → Oct 2012 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01351935 | Jul 2011 → Jun 2015 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01975610 | Oct 2013 → Jan 2016 | rheumatoid arthritis | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spebrutinib | “Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways.” PMID 31721017 ↗ Nov 2019 |
| Known as | AVL-292 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01692184 ↗ |
| Known as | AVL-292 BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | BTK INHIBITOR CC-292 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | CC-292 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01766583 ↗ |
| Known as | CC-292 BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | ESPEBRUTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | LMK-435 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | SPEBRUTINIB (CC-292) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | Spebrutinib besilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Known as | SPEBRUTINIB BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301625 ↗ |
| Action | Inhibit | “AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor” NCT01351935 ↗ |
| Modality | Small molecule | “small-molecule inhibitor of Bruton's tyrosine kinase (BTK)” PMID 31721017 ↗ Nov 2019 |
| Route | Oral | “125 mg to 625 mg orally” NCT01351935 ↗ |
| Target | BTK | “AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor” NCT01351935 ↗ |